Caicedo Dolly Andrea, Pérez-Mañá Clara, Farré Magí, Papaseit Esther
Department of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Bellaterra, 08193 Cerdanyola del Vallès, Spain.
Pharmaceutics. 2025 Mar 1;17(3):319. doi: 10.3390/pharmaceutics17030319.
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes.
大麻是全球最常用的非法物质。近年来，大麻消费量有所增加，随着新的批准和治疗适应症的出现，在将基于大麻的产品、大麻处方药、其他获批处方药和其他滥用物质之间的风险及相互作用降至最低方面存在挑战。因此，确定代谢大麻素药物的酶及其与其他处方药的关系对于理解同时使用它们的潜在相互作用和影响至关重要。本文全面综述了大麻以及大麻产品、大麻处方药和其他获批处方药以及其他滥用物质之间的药代动力学相互作用。它还汇编了这些相互作用的现有证据，并描述了与各种酶的抑制或诱导相关的临床结果。
